Research programme: IRAK-4 inhibitors - Aurigene/Curis

Drug Profile

Research programme: IRAK-4 inhibitors - Aurigene/Curis

Alternative Names: CA-4948; Interleukin-1 receptor-associated kinase 4 inhibitors - Aurigene/Curis; IRAK-4 inhibitors; IRAK4 kinase inhibitors - Aurigene/Curis

Latest Information Update: 10 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Aurigene Discovery Technologies
  • Developer Aurigene Discovery Technologies; Curis
  • Class Small molecules
  • Mechanism of Action Interleukin-1 receptor-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Inflammation

Most Recent Events

  • 07 Nov 2017 US FDA approves IND application for CA 4948 in Non-Hodgkin's lymphoma
  • 01 Nov 2017 Curis plans a phase I trial for Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in USA (NCT03328078)
  • 29 Feb 2016 Curis plans a phase I trial for Haematological malignancies in USA (Curis, Form 10-K, February 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top